目的：分析CTOP方案化疗联合利妥昔单抗治疗弥漫大B细胞淋巴瘤的效果及对患者血清胸苷激酶1（TK1）、β₂-微球蛋白（β₂-MG）水平的影响。方法：将2015年1月至2017年4月本院收治的100例弥漫大B细胞淋巴瘤患者随机分为观察组与对照组，每组50例。对照组采用CTOP化疗方案治疗，观察组采用CTOP化疗方案联合利妥昔单抗治疗。治疗结束后对患者临床疗效及不良反应进行评估，并检测治疗前后患者血清TK1、β₂-MG水平。结果：治疗后观察组治疗总有效率为84%，显著高于对照组的50%（P<0.05）；治疗前两组患者血清中TK1、β₂-MG水平差异均无统计学意义（P>0.05），治疗后两组血中TK1、β₂-MG水平均显著降低（P<0.05），且观察组患者血中TK1、β₂-MG水平均显著低于对照组（P<0.05）。结论：CTOP方案化疗联合利妥昔单抗治疗弥漫大B细胞淋巴瘤可显著提高临床效果，并降低患者血清TK1与β₂-MG水平。

[1] BACHANOVA V,SARHAN D,DEFOR T E,et al.Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells[J].Cancer Immunol Immunother,2018,67(3):483-494.
[2] MIZIA-STEC K,ELÅBIECIAK M,WYBRANIEC M T,et al.Chemotherapy and echocardiographic indices in patients with non-Hodgkin lymphoma:the ONCO-ECHO study[J].Med Oncol,2018,35(1):14.
[3] 李岩,刘爱春.弥漫大B细胞淋巴瘤预后相关因素研究进展[J].东南大学学报(医学版),2018,36(3):95-98.
[4] MATSUBARA S,SUZUKI S,HORIUCHI J,et al.Peripheral lymphocyte count in untreated non-Hodgkin's lymphoma patients and their lymphographic findings[J].Lymphology,2017,13(4):192-196.
[5] RIBEIRO T H,FILHO S R,CASTRO A C,et al.Targeting personalized medicine in a non-Hodgkin lymphoma patient with 18F-FDG and 18F-choline PET/CT[J].Revista Da Associacao Medica Brasileira,2017,63(2):109-111.
[6] 袁媛,李金娇,肖荦,等.Ann Arbor分期划分淋巴瘤淋巴结区域的意义探讨[J].中国现代医学杂志,2017,27(10):107-111.
[7] 宋腾,王华庆,张会来,等.改良国际预后指数(NCCN-IPI)对R-CHOP方案治疗弥漫大B细胞淋巴瘤的预后评估(附168例临床分析)[J].中国肿瘤临床,2015,42(21):1050-1055.
[8] 侯思远,杨威.我国美罗华联合CHOP方案化疗对非霍奇金淋巴瘤疗效的Meta分析[J].中国全科医学,2011,14(12):1331-1333.
[9] 许伟,丁现超,任小晶.沙利度胺联合CHOP方案治疗外周T细胞淋巴瘤的临床研究[J].现代药物与临床,2017,6(5):98-101.
[10] 单永锋,王彩莲,姜藻,等.载阿霉素的磁性微泡双模式的成像效果及其对淋巴瘤细胞毒性的研究[J].东南大学学报(医学版),2015,6(3):87-91.
[11] 杨付珍,王开云,田智萍.用含吡柔比星的化疗方案对老年非霍奇金淋巴瘤患者进行治疗的效果探析[J].当代医药论丛,2017,15(20):74-75.
[12] ZHANG X,ZHENG G,CHEN B,et al.Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma:a meta-analysis[J].Medicine,2017,96(33):e7781.
[13] 刘昕,冯正富,赖志伟,等.肿瘤患者治疗前后血清中TK1表达的差异[J].现代医院,2016,16(6):848-850.
[14] GRAVELLE P,BURRONI B,PÉRICART S,et al.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma:a summary of immunohistochemical studies[J].Oncotarget,2017,8(27):44960-44975.
[15] LU B,SHEN X,ZHANG L,et al.Discovery of EBI-2511:a highly potent and orally active EZH2 inhibitor for the treatment of non-Hodgkin's lymphoma[J].ACS Med Chem Lett,2018,9(2):98.